Vacuum-assisted breast biopsy on digital stereotaxic table of nonpalpable lesions non-recognisable by ultrasonography

The aim of this study was to evaluate accuracy of 11 G vacuum-assisted percutaneous biopsy (VAPB) carried out on digital stereotaxic table, on breast non-palpable lesions (NPLs), non-visible by US. Prospective study on 132 consecutive NPLs (126 patients) not reliably found by US; 82% showed microcalcifications. Surgical confirmation was obtained in all malignant cases and when VAPB reported atypical lesion (ductal or lobular), radial scar or atypical papillary lesion. All patients with benign results were included in a mammographic follow-up programme. Two cases could not be dealt with due to technical difficulties. One to 26 cylinders were obtained from the remaining 130 NPLs. Sixty-four lesions were surgically confirmed. Forty-six of the 47 malignancies were correctly diagnosed. In one case of a malignant tumour, an atypical lesion was classified with VAPB. All cases of histologically verified lobular carcinoma in situ, atypical ductal or lobular hyperplasia, radial scar or atypical papillary lesion were correctly diagnosed preoperatively. The remaining lesions were benign in VAPB, and after 1 year of follow-up, no false negative has been found. Based on this short-term follow-up, absolute sensitivity was 97.9%, absolute specificity 84.3% and accuracy was 99.2%. For predicting invasion, accuracy was 89.1%. Vacuum-assisted percutaneous biopsy is a very accurate technique for NPLs which are not detectable by US. It can replace approximately 90% of DSB with no important complications, avoiding scars and providing a higher level of comfort.     

Stereotactic vacuum-assisted breast biopsy in 268 nonpalpable lesions

PURPOSE: We evaluated the reliability of stereotactic vacuum-assisted breast biopsies (VAB) from our personal experience. MATERIALS AND METHODS: Between January 2003 and December 2005, 268 patients underwent VAB with an 11-gauge probe at our institution. Inclusion criteria were nonpalpable lesions, undetectable by ultrasound and suspected at mammography (microcalcifications, circumscribed mass, architectural distortion), for which cytology and/or core biopsy could not provide a definite diagnosis. Lesion mammographic patterns were microcalcifications in 186 cases (77.5%), mostly localised clusters (130/186: 70%); circumscribed mass with or without microcalcifications in 36 cases (15%) and architectural distortion with or without microcalcifications in 18 cases (7.5%). On the basis of the Breast Imaging Reporting and Data System (BI-RADS) classification, 16 cases (7%) were graded as highly suspicious for malignancy (BI-RADS 5), 81 (34%) as suspicious for malignancy (BI-RADS 4b), 97 (40%) as indeterminate (BI-RADS 4a) and 46 (19%) as probably benign (BI-RADS 3). Lesion size was 20 mm in only 38 cases (16%), 30 of which appeared as microcalcifications. RESULTS: In 28/268 lesions (10.5%) the biopsy could not be performed (nonidentification of the lesion; inaccessibility due to location or breast size). In 12/240 (5%) biopsies, the sample was not representative. Pathology revealed 100/240 (42%) malignant or borderline lesions and 140/240 (58%) benign lesions. Among the malignant lesions, 16/100 (16%) were invasive carcinoma [infiltrating ductal carcinoma (IDC) or infiltrating lobular carcinoma (ILC)], 13/100 (13%) were microinvasive (T1mic), 35/100 (35%) were ductal carcinoma in situ (DCIS), 9/100 (9%) were lobular carcinoma in situ (CLIS). Among the borderline lesions, 27/100 (27%) were atypical epithelial hyperplasia [atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH)]. In 9/100 surgically treated lesions (9%), there was discordance between the microhistological findings of VAB and the pathological results of the surgical procedure: 8/9 were underestimated by VAB (four ADH vs. DCIS, three DCIS vs. IDC, one ADH vs. IDC), and 1/9 was overestimated (T1mic vs. DCIS). Complications following VAB occurred in 9/240 patients (3.7%). CONCLUSIONS: In our experience, VAB showed fair reliability in the diagnosis of nonpalpable breast lesions despite a portion of failed (10.5%), nonsignificant (5%) procedures and underestimated lesions (9%).     

立体定位导丝导向活检不能触及的乳腺病灶

目的 探讨立体定位导丝导向活检不能触及的乳腺病灶的价值。方法 对25例不能触及的乳腺病灶行立体定位导丝导向活检26处,对每处病灶计算出穿刺针针尖至病灶中心的距离（D）,并直接测量出留置的导丝头端至病灶中心的距离作对照,判断标准：优：D小于等于2．5mm;良：D＝2．6－4．9mm;差：D大于等于5．0mm。结果 定位优20例次,良5例次,差1例次。穿刺针针尖至病灶中心距离的计算值与直接测量值相符,1次性病灶切除26例次,标本体积的中位数为10．5cm3,检出乳腺癌6（6／26）处;结论 立体定位导丝导向活检不能触及的乳腺病灶能以最小的手术范围完整切除病灶,定位定性效果确切,可避免假阴性,提高了乳腺癌的早期检出率及诊断准确性。     

Stereotaxic needle-core biopsy and fine-needle aspiration biopsy in the diagnosis of nonpalpable breast lesions: controversies and future prospects

Objective: To determine the advantages and limitations of a combined stereotaxic fine-needle aspiration biopsy and needle-core biopsy in the diagnosis of 353 nonpalpable breast lesions with special attention given to the collection of follow-up data. Methods and material: 353 nonpalpable breast lesions underwent ‘one pass’ stereotaxic fine-needle aspiration (21 gauge needle) and needle-core biopsy (18 gauge needle) at our institution from January 1990 to October 1993. Stereotaxic biopsies were carried out by means of an ‘add-on unit’. Surgical biopsy was usually recommended for highly suspicious radiologic patterns and/or needle biopsy reports classified as atypical or malignant. In all other cases mammographic follow-up was advised at 6 months and then annually for 3 years. The data were collected retrospectively during September 1995 (theoretical average follow-up of greater than 3 years). Results: Following the combined needle biopsy technique procedure, surgery was recommended for 83 lesions. Fifty-four cancers were associated to these suspicious lesions. Because of changing radiological or clinical pattern during follow-up (mean follow-up: 22 months), 11 cancers were detected among the 270 lesions initially considered not to need surgery. Forty-three percent of the 65 malignant lesions were initially read as having less than highly suspicious mammographic features. There was no significant difference between the sensitivity and the specificity of one pass fine-needle aspiration biopsy (57% and 96% respectively) and needle-core biopsy (60% and 97% respectively), but noncontributive samples were not included in the false negative diagnoses and atypical samples were included in the true positive diagnoses. Of the 11 missed cancers, nine were manifested initially by clusters of calcifications. Our diagnostic approach was significantly less sensitive (P = 0.006) and less specific (P = 0.032) in cases of clusters of calcifications (31% false negative diagnoses) than in cases of soft-tissue masses (5.5% false negative diagnoses). In this study, an average delay in diagnosis of 22 months was responsible for a significantly increased percentage of axillary node positive invasive cancer (P < 0.001) and six of the 11 missed cancers were palpable at the time of the delayed diagnosis. For the nine cancers initially manifested by calcifications, the 22 months delay in diagnosis was responsible for a nonsignificant increase of microinvasive type at the expense of carcinoma in situ. Conclusion: Our enthusiasm with the sensitivity of this double stereotaxic needle sampling has been tempered by the results of this reanalysis in the light of a mean theoretical follow-up of three years. Our diagnostic approach was adequate in the presence of soft-tissue masses but not valid in the presence of clustered calcifications. When dealing with calcifications, multiple samplings must be done in order to improve the sensitivity of the diagnosis. Furthermore, this study does not favour the theory that the majority of mammographically detected cancers are indolent and highlights the poor sensitivity of the mammographic follow-up of nonpalpable lesions.     

Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates

PURPOSE: To measure the effect of biopsy device, probe size, mammographic lesion type, lesion size, and number of samples obtained per lesion on the ductal carcinoma in situ (DCIS) underestimation rate. MATERIALS AND METHODS: Nonpalpable breast lesions at 16 institutions received a histologic diagnosis of DCIS after 14-gauge automated large-core biopsy in 373 lesions and after 14- or 11-gauge directional vacuum-assisted biopsy in 953 lesions. The presence of histopathologic invasive carcinoma was noted at subsequent surgical biopsy. RESULTS: By performing the chi(2) test, independent significant DCIS underestimation rates by biopsy device were 20.4% (76 of 373) of lesions diagnosed at large-core biopsy and 11.2% (107 of 953) of lesions diagnosed at vacuum-assisted biopsy (P <.001); by lesion type, 24.3% (35 of 144) of masses and 12.5% (148 of 1,182) of microcalcifications (P <.001); and by number of specimens per lesion, 17.5% (88 of 502) with 10 or fewer specimens and 11.5% (92 of 799) with greater than 10 (P <.02). DCIS underestimations increased with lesion size. CONCLUSION: DCIS underestimations were 1.9 times more frequent with masses than with calcifications, 1.8 times more frequent with large-core biopsy than with vacuum-assisted biopsy, and 1.5 times more frequent with 10 or fewer specimens per lesion than with more than 10 specimens per lesion.     

MRI诊断扪诊阴性的乳腺占位性疾病

目的：评价ＭＲＩ诊断扪诊阴性的乳腺疾病的敏感性、特异性并探讨其临床意义。材料与方法：应用ＭＲ快速小角度激发三维成像（ＦＬＡＳＨ－３Ｄ）对２６例Ｂ超或Ｘ线检查提示或怀疑有占位，而临床检查未扪及肿块病人的乳腺进行常规及动态检查。结果：发现孤立性病灶２１个，根据病灶形态、边缘、信号均匀度及增强前后信号的动态变化确定典型癌性病变４例，典型良性病变１１例，非典型病变１１例。经病理学对照，本组病例ＭＲＩ的敏感性为１００％，特异性６５％。结论：对于典型良、恶性病变，ＭＲＩ的特异性较高，尽管对非典型良、恶性病变重叠较大，但ＭＲＩ为这类病变提供了细胞学检查和预防性手术的影像学依据。     

Mammography-guided stereotactic fine-needle aspiration cytology of nonpalpable breast lesions: prospective comparison with surgical biopsy results

We assessed the usefulness of fine-needle aspiration cytology (FNAC) in evaluating nonpalpable breast abnormalities by prospectively performing stereotactic mammography-guided FNAC on 100 women undergoing surgical excisional biopsy. Mammographic and cytologic diagnoses, on a scale of 1 (benign) to 4 (malignant), were assigned for each case and compared with the surgical pathologic diagnosis. Sensitivity and specificity were examined at different diagnostic cutoff points for regarding a mammographic or cytologic diagnosis as positive or negative. Of the 100 breast biopsy specimens, 70 were benign and 30 were malignant. For both mammography and FNAC, the optimal diagnostic cutoff point was between diagnosis 2 (mammography, probably benign; cytology, atypical) and 3 (mammography and cytology both suspicious for malignancy). At this cutoff point, FNAC had a sensitivity of 0.77 and specificity of 1.00, vs 0.73 sensitivity and 0.79 specificity for mammography. Pearson coefficient analysis revealed significant correlations between both mammographic and FNAC diagnoses and surgical pathology (p less than .001 for both). Our results suggest that use of mammography-guided FNAC may reduce the number of breast biopsies performed for benign lesions.     

Prebiopsy localization of nonpalpable breast lesions

Invasive localization procedures are indicated preoperatively when breast lesions are nonpalpable. Several techniques are available for locating such lesions. In experience with 343 nonpalpable lesions, 27% of the biopsied lesions were malignant. Calcification was present in 51% of all lesions. A combination needle-hooked wire technique was used. Some problems were encountered, the most frequent being vasovagal reactions. The most serious problem was the failure to remove the located lesion in nine cases.     

Minimal-volume excision of nonpalpable breast lesions

To explore the value of accurate preoperative localization of occult breast lesions, we reviewed 100 consecutive needle-directed breast biopsies performed by the same surgeon over a 1-year period. A spring hookwire device for localization was inserted parallel to the chest wall. Two thirds of biopsies were performed under local anesthesia, and all were performed in an outpatient setting. Sixteen lesions were invasive carcinomas, and eight were ductal carcinomas in situ. In 96 lesions, the localizing wire was placed within 2 mm of the lesion, and in the remaining four it was within 5 mm of the abnormality. The mammographic lesion was excised in the first specimen in 96 cases. One patient required a second biopsy because of failure to excise the lesion in question after three specimens were taken. The only surgical complication was one hematoma, which resolved within 3 months. Median specimen volume for the entire series was 6.0 cm3. Median largest specimen diameter was 2.5 cm. Precise preoperative localization with a spring hookwire to within 2 mm of the mammographic lesion allows the surgeon to excise a median volume of 6 cm3 breast tissue with consistent retrieval of the lesion.     

Vacuum-assisted stereotactic biopsy for isolated BI-RADS 4 microcalcifications: evaluation with histopathology and midterm follow-up results

PURPOSE

The aim of this study was to evaluate the 10-gauge vacuum-assisted stereotactic biopsy (VASB) of isolated Breast Imaging Reporting and Data System (BI-RADS) 4 microcalcifications, using histology and follow-up results.

METHODS

From January 2011 to June 2013, VASB was performed on 132 lesions, and 66 microcalcification-only lesions of BI-RADS 4 were included into our study. VASB was performed using lateral decubitis stereotaxy for all patients. Pathologic results of VASB and further surgical biopsies were reviewed retrospectively. Patients who were diagnosed to have benign lesions by VASB were referred for follow-up. VASB and surgical histopathology results were compared to determine the underestimation ratios.

RESULTS

Fifteen out of 66 lesions from 63 patients (median age, 47 years; range, 34–88 years) were identified as malignant by VASB. Pathological results after surgery revealed three cases of invasive ductal carcinoma among the 12 VASB-diagnosed ductal carcinoma in situ (DCIS) lesions, for a DCIS underestimation rate of 25%. The atypical ductal hyperplasia underestimation rate was 0% for the three lesions. The follow-up period was at least 10 months, with an average of 22.7 months for all patients and 21.2 months for patients with VASB-diagnosed benign lesions. None of the patients had malignancy during the follow-ups. The false-negative rate was 0% in the follow-up of 48 patients.

CONCLUSION

VASB should be the standard method of choice for BI-RADS 4 microcalcifications. This method obviates the need for a surgical procedure in 73% of BI-RADS 4 microcalcification-only patients.Recently, growing concern regarding breast cancer has resulted in increasingly frequent recommendations for screening mammography and more intensive requirements for biopsies of subclinical (impalpable) lesions. Microcalcifications may be the only finding of early stage malignancies, including atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). Isolated microcalcifications comprise 55% of the suspicious lesions detected by mammography (1, 2).Until recently, the most common approach for this type of pathology has been surgical excision of the lesion after wire localization by mammographic guidance. However, studies have shown that surgical excisions result in benign histology in 76%–81% of the cases (3, 4). Understandably, surgical excisions generate anxiety in most patients. Additionally, the cost and morbidity associated with the surgical procedures have prompted many physicians to explore less invasive, alternative procedures (5–7).For the past two decades, vacuum-assisted stereotactic biopsy (VASB) has been increasingly used for histologic diagnosis of suspicious microcalcifications. The 11-gauge VASB allows radiologists to obtain a sufficiently large specimen with better calcification retrieval (8), a lower re-biopsy rate, and fewer histologic underestimates (9–11), compared with other core-needle biopsy techniques. The false-negative rate of VASB procedure can be as low as 0.6% when performed by experienced radiologists (12). This technique also has some cost advantages compared to needle-localized surgical biopsy (NLSB)(13).Although numerous studies of VASB under real-time ultrasonography (US) or mammography guidance exist, none have included a sufficient subgroup analysis (2, 14). Core needle biopsy is the cheapest and easiest technique for lesions that can be visualized by US; however, isolated, suspicious microcalcifications can only be sampled by means of stereotaxy. To our knowledge, there is no study that has specifically evaluated isolated Breast Imaging Reporting and Data System (BI-RADS) 4 microcalcifications, even though these constitute the majority of subclinical lesions detected by screening mammography. BI-RADS 3 microcalcifications can be followed confidently, whereas BI-RADS 5 microcalcifications should be subjected to surgical excision in all cases.BI-RADS 4 microcalcifications are the most critical issue facing radiologists reporting screening mammography. Through the routine use of VASB for BI-RADS 4 microcalcifications, surgical excision can be avoided in most patients (3, 4). It is important to consider the underestimation and false-negative rates, specifically for isolated BI-RADS 4 microcalcifications, before considering more invasive methods (surgical biopsies) as a further step after VASB. The aim of this study was to evaluate the utility of VASB for isolated BI-RADS 4 microcalcifications by studying their midterm follow-up results.     

Vacuum-assisted large-core breast biopsy: complications and their incidence.

OBJECTIVE: To assess both the rate and types of complications associated with vacuum-assisted large-core breast biopsy (VALCBB) at our institution. METHODS: Three hundred and four VALCBBs performed in 297 patients between Sept. 18, 1997, and Mar. 30, 1999, were evaluated. Complications associated with VALCBB were assessed at the time of the procedure and in the post-procedure period. Adverse outcomes included pain, bleeding or bruising, and hematoma. Complications were also classified in terms of minor, significant, and major severity. RESULTS: VALCBB yielded non-minor (i.e., significant and major) complication rates of 3.9% during the procedure and 3.6% in the post-procedure period, with only 2 complications (vasovagal-induced seizure and migraine) that required treatment. CONCLUSION: With proper technique and patient preparation, VALCBB is a very safe procedure with a low complication rate.